Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02364544 · ClinicalTrials.gov registry record · NA
Improving Care and Reducing Cost Study
A NA study of Schizophrenia and Schizoaffective Disorder, sponsored by Northwell Health.
- Completed
- Registry status
- NA
- Development phase
- 461
- Enrollment target
- 8
- Study locations
NCT02364544: Completed NA study of Schizophrenia and Schizoaffective Disorder, sponsored by Northwell Health.
NCT02364544 is a NA study of Schizophrenia and Schizoaffective Disorder that has completed, run by Northwell Health. The registered enrollment target is 461 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (111% higher). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02364544, a NA study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 461 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of the Improving Care and Reducing Cost (ICRC) Program, is to improve disease management and the overall process of care in treating the chronic illness schizophrenia in order to reduce ER visits and hospital days while providing better care, better health and increased patient satisfaction. This will be done by fostering innovation in the use of technology and by training and deploying a new cadre of personnel in the behavioral health field: Mental Health/Health Technology (MH/HT) Case Managers.
Primary Outcome
Captures the number of hospital and ER visits each month
Conditions Studied
Interventions
- BEHAVIORAL FOCUS
- BEHAVIORAL Relapse Prevention Plan
- BEHAVIORAL Daily Support Website
- BEHAVIORAL Computer CBT for voices and paranoia
- OTHER Prescriber Decision Assistant
Study Locations (8)
Missouri
- UMKC School of Pharmacy - Kansas City
- Burrell Behavioral Health - Springfield
Florida
- Henderson Mental Health Center - Fort Lauderdale
Indiana
- Community Mental Health Center, Inc. - Lawrenceburg
Michigan
- Cherry Street - Grand Rapids
New Hampshire
- The Mental Health Center of Greater Manchester - Manchester
New Mexico
- University of New Mexico Department of Psychiatry UNM Health Sciences Center - Albuquerque
Oregon
- PeaceHealth Oregon/Lane County Behavioral Health Services - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 461 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-06 |
| Phase | NA |
What the finished NCT02364544 record still lists
NCT02364544 is an interventional study that assigns participants to a tested intervention. The registered 461 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (111% higher).
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 5 interventions - of which FOCUS is the first listed.
NCT02364544 lists 8 locations in 7 states (Missouri, Florida, Indiana).
Frequently Asked Questions
What is clinical trial NCT02364544 about?
NCT02364544 is a clinical study titled "Improving Care and Reducing Cost Study". The goal of the Improving Care and Reducing Cost (ICRC) Program, is to improve disease management and the overall process of care in treating the chronic illness schizophrenia in order to reduce ER visits and hospital days while providing better care, better health and increased patient satisfaction...
What is the current status of trial NCT02364544?
This trial is currently completed. It is a NA study. The enrollment target is 461 participants. The study started on 2013-04. Estimated completion is 2015-06.
What conditions does trial NCT02364544 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder, Psychosis NOS.
What interventions are being tested in trial NCT02364544?
The interventions under investigation include: FOCUS (BEHAVIORAL), Relapse Prevention Plan (BEHAVIORAL), Daily Support Website (BEHAVIORAL), Computer CBT for voices and paranoia (BEHAVIORAL), Prescriber Decision Assistant (OTHER).
Who is sponsoring clinical trial NCT02364544?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02364544 being conducted?
This trial has 8 study locations across Florida, Indiana, Michigan, Missouri, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02364544's enrollment target sits among peer trials
461 41st of 315 higher than 275 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04546399 · 461 participants · Phase 2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT00949819 · 462 participants
Active Surveillance for Cancer of the Prostate (ASCaP)
- NCT05126277 · 462 participants · Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia